Lasa Supergenerics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lasa Supergenerics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	18.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues

Aug 08

We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

Jun 05

Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding

Mar 13

Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified

Dec 28

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lasa Supergenerics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:LASA - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	1,046	-195	N/A	N/A	N/A
3/31/2024	1,044	-217	21	21	N/A
12/31/2023	1,168	-214	N/A	N/A	N/A
9/30/2023	1,219	-249	-54	-50	N/A
6/30/2023	1,312	-315	N/A	N/A	N/A
3/31/2023	1,304	-386	-173	-173	N/A
12/31/2022	1,455	-113	N/A	N/A	N/A
9/30/2022	1,295	-111	49	62	N/A
6/30/2022	1,299	-183	N/A	N/A	N/A
3/31/2022	1,371	-53	92	92	N/A
12/31/2021	1,250	-139	N/A	N/A	N/A
9/30/2021	1,633	-26	26	92	N/A
6/30/2021	1,838	182	N/A	N/A	N/A
3/31/2021	2,024	228	347	413	N/A
12/31/2020	2,118	216	N/A	N/A	N/A
9/30/2020	1,972	176	272	264	N/A
6/30/2020	1,829	101	N/A	N/A	N/A
3/31/2020	1,673	36	130	136	N/A
12/31/2019	1,607	-8	N/A	N/A	N/A
9/30/2019	1,753	-86	N/A	N/A	N/A
6/30/2019	1,756	-101	N/A	N/A	N/A
3/31/2019	1,696	-120	293	407	N/A
12/31/2018	1,869	-167	N/A	N/A	N/A
9/30/2018	1,940	-83	N/A	N/A	N/A
6/30/2018	2,175	55	N/A	N/A	N/A
3/31/2018	2,435	123	N/A	404	N/A
6/30/2017	2,184	-10	N/A	N/A	N/A
3/31/2017	2,182	24	N/A	-30	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LASA's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if LASA's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if LASA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LASA's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if LASA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LASA's Return on Equity is forecast to be high in 3 years time

Lasa Supergenerics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Lasa Supergenerics Limited to Report Q2, 2025 Results on Nov 14, 2024

New major risk - Share price stability

Lasa Supergenerics Limited, Annual General Meeting, Sep 27, 2024

Lasa Supergenerics Limited, Annual General Meeting, Sep 27, 2024

New minor risk - Share price stability

First quarter 2025 earnings released: ₹0.55 loss per share (vs ₹0.99 loss in 1Q 2024)

There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues

Lasa Supergenerics Limited to Report Q1, 2025 Results on Aug 14, 2024

We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

Full year 2024 earnings released: ₹4.34 loss per share (vs ₹7.71 loss in FY 2023)

Lasa Supergenerics Limited to Report Q4, 2024 Results on May 30, 2024

Lasa Supergenerics Limited Announces Resignation of Ravi Shankar Kabra as Chief Financial Officer

Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding

Lasa Supergenerics Limited Appoints Umesh Pawar as an Additional Director (Executive Director)

Third quarter 2024 earnings released: ₹0.29 loss per share (vs ₹1.21 loss in 3Q 2023)

Lasa Supergenerics Limited to Report Q3, 2024 Results on Feb 13, 2024

Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified

Second quarter 2024 earnings released: ₹0.005 loss per share (vs ₹1.62 loss in 2Q 2023)

Lasa Supergenerics Limited to Report Q2, 2024 Results on Nov 10, 2023

Lasa Supergenerics Limited, Annual General Meeting, Sep 27, 2023

First quarter 2024 earnings released: ₹0.99 loss per share (vs ₹2.97 loss in 1Q 2023)

Lasa Supergenerics Limited to Report Q1, 2024 Results on Aug 14, 2023

We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

New major risk - Financial position

Full year 2023 earnings released: ₹7.71 loss per share (vs ₹1.32 loss in FY 2022)

Lasa Supergenerics Limited to Report Q4, 2023 Results on May 29, 2023

Lasa Supergenerics (NSE:LASA) Is Carrying A Fair Bit Of Debt

Third quarter 2023 earnings released: ₹1.21 loss per share (vs ₹1.16 loss in 3Q 2022)

Lasa Supergenerics Limited Announces Resignation of Ankita Shetty as Company Secretary and Compliance Officer

Lasa Supergenerics Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: ₹1.62 loss per share (vs ₹3.38 loss in 2Q 2022)

Insufficient new directors

Lasa Supergenerics Limited to Report Q2, 2023 Results on Nov 14, 2022

Upcoming dividend of ₹0.25 per share

Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25

Lasa Supergenerics Limited, Annual General Meeting, Sep 26, 2022

Would Lasa Supergenerics (NSE:LASA) Be Better Off With Less Debt?

First quarter 2023 earnings released: ₹2.97 loss per share (vs ₹0.20 profit in 1Q 2022)

Lasa Supergenerics Limited to Report Q1, 2023 Results on Aug 08, 2022

A Look At The Fair Value Of Lasa Supergenerics Limited (NSE:LASA)

Lasa Supergenerics Limited Announces Resignation of Mithun Mohan Jadhav as Director

Insufficient new directors

Lasa Supergenerics Limited Approves the Recommendation of the Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings released: ₹1.32 loss per share (vs ₹5.60 profit in FY 2021)

Lasa Supergenerics Limited to Report Q4, 2022 Results on Apr 11, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Is Lasa Supergenerics (NSE:LASA) Using Too Much Debt?

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Lasa Supergenerics Limited Launches New Product - Oxyclozanide

Full year 2021 earnings released: EPS ₹5.60 (vs ₹0.89 in FY 2020)

Lasa Supergenerics Limited Approves Final Dividend for the Financial Year Ended March 31, 2021

Investor sentiment improved over the past week

New 90-day low: ₹66.60

New 90-day low: ₹74.55

Third quarter 2021 earnings released: EPS ₹1.61 (vs ₹0.89 in 3Q 2020)

Lasa Supergenerics Limited to Report Q3, 2020 Results on Feb 01, 2021

New 90-day high: ₹88.20

New 90-day high: ₹88.00

New 90-day high: ₹81.05

New 90-day high: ₹76.55

Market bids up stock over the past week

New 90-day high - ₹71.90

New 90-day high - ₹66.95

Lasa Supergenerics Limited to Report Q1, 2021 Results on Aug 05, 2020

New 90-day high - ₹55.65

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies